<DOC>
	<DOCNO>NCT01071161</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy azithromycin produce significant change cough-related health status , measure Dutch version Leicester Cough Questionnaire patiÃ«nts COPD gold classification 2-4 chronic productive coughing .</brief_summary>
	<brief_title>The Effect Azithromycin Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Chronic Productive Cough</brief_title>
	<detailed_description>This study prospective double-centre , double blind randomise trial . Patients &gt; 40 year age , refer outpatient clinic chronic cough sputum production due COPD recruit informed consent obtain . Consenting patient randomise 12-week treatment 250 mg azithromycin three time week placebo . Before randomisation patient fill SF 36 , SGRQ Dutch version Leicester Cough Questionnaire ( LCQ ) assessment baseline quality life disease specific quality life . The LCQ questionnaire perform begin every 3 week afterwards 18 week , except second LCQ fill 2 week . Scores questionnaire use calculate 2-week repeatability . The SF 36 SGRQ perform start study 12 week . Adverse event record whole treatment period . After 2 12 week Global Rating Change perform . This questionnaire use validate LCQ COPD patient . Randomisation take place use computer allocation program ( BAMI-computer ) Azithromycin placebo provide Teva Pharmaceuticals . Placebo azithromycin identical appearance packaging .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Patients &gt; 40 year age , outpatient clinic chronic cough COPD ( gold24 ) Chronic cough define cough &gt; 12 week duration , least 12 week year 2 subsequent year . Analysed bronchiectasis prior participation CTthorax . Prior history asthma Use i.v . oral corticosteroid antibiotic exacerbation 3 week inclusion Patients suffer relevant lung disease . Clinically relevant abnormal laboratory value suggest unknown disease require clinical evaluation . Liver disease , ( ALAT and/or ASAT level two time upper limit normal ) . Pregnancy lactation . Use macrolides last 6 week prior inclusion . Allergy intolerance macrolides . Other research medication start 2 month prior inclusion . Prior randomisation study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>chronic cough</keyword>
	<keyword>COPD</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Zithromax</keyword>
	<keyword>LCQ</keyword>
</DOC>